Sulfonylureas may increase risk of death in type 2 diabetes patients

09/26/2013 | U.S. News & World Report

British researchers found type 2 diabetes patients who used sulfonylureas as an initial treatment had a 58% higher risk of all-cause mortality compared with those who were on metformin monotherapy. While more data are needed, the results suggest using sulfonylureas as first-line monotherapy "should be reconsidered," researchers reported at the European Association for the Study of Diabetes meeting.

View Full Article in:

U.S. News & World Report

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX